Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corp (Nasdaq: LUNG) delivers innovative minimally invasive solutions for severe lung diseases, including its FDA-cleared Zephyr Valve system. This news hub provides essential updates for stakeholders tracking medical advancements and corporate developments in interventional pulmonology.
Access real-time updates on clinical trial milestones, regulatory approvals, and strategic partnerships that shape treatment paradigms for emphysema and COPD. Our curated collection features earnings reports, product launch details, and peer-reviewed research findings - all vital for understanding Pulmonx's market position.
Key content includes analysis of pulmonary treatment innovations, global commercialization efforts, and financial performance metrics. Investors and healthcare professionals will find timely information on FDA submissions, international expansion, and clinical outcome studies that demonstrate improved patient quality of life.
Bookmark this page for centralized access to Pulmonx's latest advancements in bronchoscopic lung volume reduction technology. Stay informed about developments that impact both respiratory care standards and long-term corporate growth strategies.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 9, 2023, at 3:55 PM PT / 6:55 PM ET. The presentation will be accessible via a live and archived webcast on the company’s website.
Pulmonx is known for its Zephyr® Endobronchial Valve, which treats patients with severe emphysema/COPD. This device has received FDA pre-market approval as a breakthrough device and is available in over 25 countries. With more than 100,000 valves employed, over 25,000 patients have been treated worldwide.
Pulmonx Corporation (Nasdaq: LUNG) plans to release its financial results for Q1 2023 on Tuesday, May 2, 2023, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Pulmonx is recognized for its innovative treatments for lung diseases, particularly the Zephyr® Endobronchial Valve, which has received FDA pre-market approval as a breakthrough device. The company has successfully deployed over 100,000 valves to treat more than 25,000 patients globally, illustrating its significant market presence and commitment to advancing pulmonary care.
Pulmonx Corporation (LUNG) reported strong financial results for Q4 and full year 2022, achieving a record worldwide revenue of $53.7 million, an 11% increase from 2021. Q4 revenue reached $15.4 million, marking a 13% year-over-year growth. U.S. revenue for 2022 increased by 30% to $32.5 million, while international revenue saw a 10% decline to $21.2 million. The gross margin was stable at 74% for the year. Despite a net loss of $58.9 million in 2022, Pulmonx expects revenue for 2023 to rise to between $63 million and $65 million.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the Citi 2023 Healthcare Conference on March 2, 2023, at 10:15 AM PT / 1:15 PM ET. The event will be accessible via a live and archived webcast on the company’s Investors section of their website.
Pulmonx is known for its Zephyr® Endobronchial Valve and related systems used extensively in treating severe emphysema/COPD, with over 100,000 valves utilized in more than 25,000 patients worldwide.
Pulmonx Corporation (Nasdaq: LUNG) will announce its financial results for Q4 and full year 2022 on February 22, 2023, after market close. The management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been commercially available in over 25 countries and used to treat more than 25,000 patients.
Investors can access a live and archived webcast of the event on the Investors section of the Pulmonx website.
Pulmonx Corporation has partnered with the American Lung Association to enhance education on Endobronchial Valves, a treatment for severe COPD. This initiative focuses on raising awareness among patients and healthcare providers about available treatment options. The campaign aims to empower individuals living with COPD by highlighting the minimally invasive nature of Endobronchial Valves, which can significantly improve quality of life. With over 25,000 patients treated with the Zephyr Valves, this collaboration seeks to expand treatment accessibility and knowledge.
Pulmonx Corporation announced the approval of the Zephyr Endobronchial Valve in Japan for treating severe COPD/emphysema patients. The Japanese Ministry of Health has validated the product following a positive PMDA recommendation, emphasizing significant patient benefits such as improved lung function and quality of life. With over 600,000 Japanese patients suffering from severe COPD, this minimally invasive procedure offers a new alternative to traditional invasive surgeries. Pulmonx aims to collaborate for reimbursement strategies prior to commercialization.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
